Foghorn Therapeutics Inc. (FHTX) Stock

Foghorn Therapeutics Inc. (FHTX) is a Healthcare stock trading at $7.08 (as of 2026-08-21), with a market capitalization of $420.74M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Foghorn Therapeutics Inc. is a biopharmaceutical company developing small-molecule therapies that modulate genetically determined chromatin regulatory dependencies, including inhibitors and protein degraders targeting BRG1/BRM, BRD9, and other chromatin regulators such as BRM and ARID1B. Its programs are aimed at treating metastatic uveal melanoma, relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and certain cancers including synovial sarcoma and ovarian, endometrial, colorectal, bladder, and gastric cancers.

Understand Foghorn Therapeutics Inc.: how it makes money

Foghorn Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops medicines using its Gene Traffic Control platform, and it is developing FHD-286 and FHD-609, while its near-term revenue currently comes from collaboration revenue.

As a clinical-stage biopharma, the company’s near-term economics depend on collaboration revenue rather than product sales, so the profit model is closely tied to whether partners fund development through collaborations.

Revenue by segment (latest quarter)
Collab$0.0B

Business quality (Weak): Limited segment detail is available (only collaboration revenue, shown as 0.0B), and the latest quarter shows no revenue, so visibility into operating momentum is constrained.

Bull case

  • Platform and pipeline focus: The company uses its proprietary Gene Traffic Control platform to identify and validate drug targets in the chromatin regulatory system, and it is developing FHD-286 and FHD-609.
  • Collaboration-funded model can support development: Its reported revenue line is collaboration revenue, which, if it resumes or grows, can support ongoing R and D activity.

Bear case

  • No revenue in the latest quarter: Revenue is 0.0B for the period ended 2026-03-31.
  • Large operating losses: The operating margin is -660.3% for the period ended 2026-03-31.
  • Business still depends on early-stage development: Being described as a clinical-stage biopharmaceutical company implies the timeline to commercial revenue is uncertain.
Valuation — source: SEC EDGAR (first-party)
Price$7.08
Market Cap$420.74M
Price / Sales13.68
FCF Yield-37.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$30.91M
Net Margin-240.3%
Revenue Growth (YoY)36.8%
EPS Growth (YoY)-25.3%
FCF Growth (YoY)-15.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.31 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFlagship Pioneering, LLC ($60.58M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAdrian H. Gottschalk
Employees112
CountryUS
IPO Date2020-10-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Benitec Biopharma Inc. (BNTC)
  • BioAge Labs, Inc. (BIOA)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Rocket Pharmaceuticals, Inc. (RCKT)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Lyell Immunopharma, Inc. (LYEL)
  • Upstream Bio, Inc. (UPB)
FHTX earnings history · FHTX institutional & insider holders · FHTX KPIs & operating metrics · FHTX financials · FHTX investor presentations & press releases · FHTX SEC filings · FHTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.